Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
YsYKth7wd58vvCJb
Listen
